VIVUS, Inc. (VVUS) EPS Estimated At $-0.11

October 13, 2018 - By Richard Conner

Investors sentiment decreased to 0.69 in 2018 Q2. Its down 0.31, from 1 in 2018Q1. It fall, as 10 investors sold VIVUS, Inc. shares while 16 reduced holdings. 11 funds opened positions while 7 raised stakes. 18.50 million shares or 15.99% less from 22.03 million shares in 2018Q1 were reported.
First Tru Advsrs L P invested in 112,975 shares. Financial Architects owns 4,000 shares. Hanson Mcclain Inc reported 0% of its portfolio in VIVUS, Inc. (NASDAQ:VVUS). State Bank Of Montreal Can accumulated 0% or 60,000 shares. 28,000 were reported by Caprock Grp Inc. Goldman Sachs Group reported 0% of its portfolio in VIVUS, Inc. (NASDAQ:VVUS). Jane Street Limited Com invested 0% of its portfolio in VIVUS, Inc. (NASDAQ:VVUS). Maple Cap Mngmt reported 0% in VIVUS, Inc. (NASDAQ:VVUS). Wells Fargo Commerce Mn reported 1,793 shares. Benjamin F Edwards invested in 0% or 200 shares. Morgan Stanley has invested 0% of its portfolio in VIVUS, Inc. (NASDAQ:VVUS). Sg Americas Lc holds 0% or 20,175 shares in its portfolio. Invesco Ltd has 0% invested in VIVUS, Inc. (NASDAQ:VVUS). Glenmede Trust Na owns 2,500 shares. Pnc Financial Ser Group Incorporated has invested 0% in VIVUS, Inc. (NASDAQ:VVUS).

Analysts expect VIVUS, Inc. (NASDAQ:VVUS) to report $-0.11 EPS on November, 6.They anticipate $0.05 EPS change or 83.33 % from last quarter’s $-0.06 EPS. After having $-0.12 EPS previously, VIVUS, Inc.’s analysts see -8.33 % EPS growth. The stock increased 4.18% or $0.19 during the last trading session, reaching $4.74. About 59,621 shares traded. VIVUS, Inc. (NASDAQ:VVUS) has declined 38.95% since October 14, 2017 and is downtrending. It has underperformed by 54.57% the S&P500.

VIVUS, Inc., a biopharmaceutical company, develops and commercializes therapies to address unmet medical needs in the United States and the European Union. The company has market cap of $50.50 million. The firm offers Qsymia for the treatment of obesity as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index of 30 or greater, or 27 or greater in the presence of at least one weight-related comorbidity, such as hypertension, type 2 diabetes mellitus or high cholesterol; and STENDRA, an oral phosphodiesterase type 5 inhibitor for the treatment of erectile dysfunction. It currently has negative earnings. It is also developing Qsymia, which has completed Phase II studies for the treatment of obstructive sleep apnea and diabetes, as well as for other obesity-related diseases, including nonalcoholic steatohepatitis, nonalcoholic fatty liver disease, hyperlipidemia, and hypertension.

More news for VIVUS, Inc. (NASDAQ:VVUS) were recently published by:, which released: “VIVUS Regains Compliance with Nasdaq Listing Requirements” on September 26, 2018.‘s article titled: “VIVUS to Present at the BIO Investor Forum on October 17, 2018” and published on October 10, 2018 is yet another important article.

VIVUS, Inc. (NASDAQ:VVUS) Institutional Positions Chart

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.